Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLJT-001
- Development stage
- Preclinical
- Lead developer
- Panlong Pharmaceutical
- Modality
- Small Molecules
01
Overview
PLJT-001 is an innovative small molecule drug candidate being developed by Panlong Pharma for the treatment of orthopedic pain. As of early 2024, the asset is in the IND-enabling phase, with the developer preparing for Investigational New Drug (IND) applications. The drug represents Panlong Pharma's strategic expansion into the development of Class 1 innovative chemical drugs, complementing its established portfolio of traditional Chinese medicines for musculoskeletal disorders. While the specific biological target and mechanism of action have not been publicly disclosed, the compound is designed to address unmet therapeutic needs in the management of pain associated with orthopedic conditions.
Beyond the preview
Go deeper on PLJT-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLJT-001.